SCHEDULE: Lynx1 Capital Discloses 8.1% Stake in Stoke Therapeutics

Lynx1 Capital Management LP has reported an 8.1% beneficial ownership stake in Stoke Therapeutics, Inc. as of March 31, 2026.

Summary

• Lynx1 Capital Management LP and Weston Nichols have filed a Schedule 13G reporting beneficial ownership of 4,763,673 shares of Stoke Therapeutics, Inc. common stock.
• This holding represents 8.1% of the company's total outstanding common stock, based on 59,150,790 shares outstanding as of February 28, 2026.
• The shares are held by Lynx1 Master Fund LP and a managed account, with Lynx1 Capital Management LP acting as the investment manager.
• The reporting persons certify that the shares were acquired for investment purposes and not to influence or change the control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development, as it reflects institutional interest and confidence in the company's equity without indicating any immediate corporate turmoil or activist pressure.

Positives

• Institutional investor confidence is demonstrated by the accumulation of an 8.1% stake in the company.
• The filing confirms the investment is passive, indicating no immediate intent to disrupt corporate governance or management strategy.

Negatives

• Increased concentration of ownership by a single investment manager may lead to higher volatility if the fund decides to divest its position.

Risks

• Market risk associated with the potential future sale of a significant block of shares by the reporting persons.
• General investment risks inherent in the biotechnology sector, where Stoke Therapeutics operates.

Future Outlook

The reporting persons have certified that the securities were not acquired for the purpose of changing or influencing the control of the issuer, suggesting a long-term investment perspective without immediate strategic intervention.

Industry Context

StockSavvy.ai notes that institutional accumulation of biotech stocks often signals confidence in the company's clinical pipeline or valuation, though it remains a standard regulatory disclosure for funds crossing the 5% ownership threshold.

Comparison to Industry Standards

• The filing follows standard SEC requirements for institutional investors (13G) who maintain passive investment strategies.
• An 8.1% stake is a significant but common position for specialized healthcare and biotech investment funds.

Related Party Transactions

• Lynx1 Fund has the right to receive dividends or proceeds from the sale of the reported shares.

Stakeholder Impact

• Shareholders may view the increased institutional ownership as a validation of the company's market position.

Next Steps

• Continued monitoring of future 13G/13F filings to track any changes in the position size by Lynx1 Capital Management.

Key Dates

Keywords

Stoke Therapeutics, Lynx1 Capital, Schedule 13G, Beneficial Ownership, Biotech, Stock Accumulation